Physician profile
David Wayne Jackson
NPI 1114996576
$5,109.77
in general payments reported to CMS, 2019-2025
16 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $129 · 2021: $580 · 2022: $55.87 · 2023: $882 · 2024: $1,857 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Consulting Fee: $1,400 · Travel and Lodging: $40.71 · Gift: $36.07 · Education: $5.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.42 |
| Consulting Fee | $1,400.00 |
| Travel and Lodging | $40.71 |
| Gift | $36.07 |
| Education | $5.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,829.73 | 2022-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol, Miebo |
| Carl Zeiss Meditec USA, INC. | $992.02 | 2021-2025 | Visumax |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $714.89 | 2019-2021 | |
| Alcon Vision LLC | $277.13 | 2019-2025 | Clareon, Simbrinza, Argos |
| Ocular Therapeutix, INC. | $227.07 | 2021-2025 | Dextenza |
| Nova Eye, INC. | $206.15 | 2023 | |
| Carl Zeiss Meditec, INC. | $177.90 | 2023 | Lumera 700, Artevo 800 |
| Ellexiscience | $161.22 | 2019 | |
| Glaukos Corporation | $120.67 | 2019-2025 | Idosetr, Idose, Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $112.53 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Star S4 Ir |
| Allergan, INC. | $90.00 | 2020 | |
| Haag-Streit USA, INC. | $79.63 | 2023 | |
| Sight Sciences, INC. | $51.42 | 2019 | |
| Harrow Eye, LLC | $36.36 | 2025 | Triesence |
| Tarsus Pharmaceuticals, INC. | $18.52 | 2024 | Xdemvy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.